Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 14Gastrointestinal 9Tumor-Agnostic 2Head & Neck 2Sarcoma 1Genitourinary 1

Conditions

Neoplasms 1Adenocarcinoma 1

Interventions

pembrolizumab 26Specimen Handling 22Biopsy 22Magnetic Resonance Spectroscopy 20Paclitaxel 12Carboplatin 10Blood Specimen Collection 10Bevacizumab 10atezolizumab 9Standard of Care 9Nivolumab 9Cisplatin 8Radiosurgery 7Pemetrexed 7Gemcitabine 6Cyclophosphamide 6Capecitabine 6trastuzumab deruxtecan 5durvalumab 5X-Rays 5Taxes 5Surveys and Questionnaires 5Irinotecan 5Fluorouracil 5olaparib 4niraparib 4cabozantinib 4Radiotherapy 4Oxaliplatin 4Leucovorin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Ramucirumab × Tumor-Agnostic × 90 days × Clear all
NCT05365581 2026-05-28

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

Astellas Pharma Inc

Phase 1 Recruiting
398 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT05999994 2026-03-27

CAMPFIRE

Eli Lilly and Company

Phase 2 Recruiting
105 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡